These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32324651)

  • 21. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
    Levine A; Wine E; Assa A; Sigall Boneh R; Shaoul R; Kori M; Cohen S; Peleg S; Shamaly H; On A; Millman P; Abramas L; Ziv-Baran T; Grant S; Abitbol G; Dunn KA; Bielawski JP; Van Limbergen J
    Gastroenterology; 2019 Aug; 157(2):440-450.e8. PubMed ID: 31170412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
    Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies.
    Bamberger S; Martinez Vinson C; Mohamed D; Viala J; Carel JC; Hugot JP; Simon D
    PLoS One; 2016; 11(9):e0163126. PubMed ID: 27636201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.
    Rubin DT; Mulani P; Chao J; Pollack PF; Bensimon AG; Yu AP; Ghosh S
    Inflamm Bowel Dis; 2012 May; 18(5):818-25. PubMed ID: 21887727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
    Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A
    BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study.
    Levine A; Turner D; Pfeffer Gik T; Amil Dias J; Veres G; Shaoul R; Staiano A; Escher J; Kolho KL; Paerregaard A; Martin de Carpi J; Veereman Wauters G; Koletzko S; Shevah O; Finnby L; Sladek M
    Inflamm Bowel Dis; 2014 Feb; 20(2):278-85. PubMed ID: 24390062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.
    Church PC; Guan J; Walters TD; Frost K; Assa A; Muise AM; Griffiths AM
    Inflamm Bowel Dis; 2014 Jul; 20(7):1177-86. PubMed ID: 24865777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
    Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
    Ungaro RC; Yzet C; Bossuyt P; Baert FJ; Vanasek T; D'Haens GR; Joustra VW; Panaccione R; Novacek G; Reinisch W; Armuzzi A; Golovchenko O; Prymak O; Goldis A; Travis SP; Hébuterne X; Ferrante M; Rogler G; Fumery M; Danese S; Rydzewska G; Pariente B; Hertervig E; Stanciu C; Serrero M; Diculescu M; Peyrin-Biroulet L; Laharie D; Wright JP; Gomollón F; Gubonina I; Schreiber S; Motoya S; Hellström PM; Halfvarson J; Butler JW; Petersson J; Petralia F; Colombel JF
    Gastroenterology; 2020 Jul; 159(1):139-147. PubMed ID: 32224129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
    Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.